IMMUNOGENICITY OUTCOMES OF A RANDOMIZED, MULTICENTER, INTERVENTIONAL, FIRST-IN-HUMAN, PHASE 1/2A STUDY OF VAC52416 (EXPEC10V), A VACCINE CANDIDATE FOR THE PREVENTION OF INVASIVE ESCHERICHIA COLI DISEASE

Autor: C. Fierro, M. Sarnecki, J. Doua, B. Spiessens, O. Go, T. Davies, G. van den Dobbelsteen, J. Poolman, D. Abbanat, W. Haazen

Publikováno v: International Journal of Infectious Diseases, Vol 130, Iss , Pp S114- (2023)

Intro: The safety, reactogenicity, and immunogenicity of VAC52416 (ExPEC10V), a vaccine candidate to prevent invasive Escherichia coli disease, was assessed in a phase 1/2a study (NCT03819049). Results from Cohort 1 have been presented. Here, we desc

Externí odkaz: https://doaj.org/article/a36a232fb4da4ef2b3ec496180426a04

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlandsf and its impact on decision-making

Autor: H.C. Rumke, H.E. de Melker, Maarten J. Postma, JM Bos, G van den Dobbelsteen, L van Alphen, Robert Welte, Lodewijk Spanjaard

Publikováno v: Vaccine, 23, 470-479. Elsevier
Vaccine, 23(4), 470-479. Elsevier BV
Vaccine, 23(4), 470-479. ELSEVIER SCI LTD

The cost-effectiveness of one time vaccination of all persons aged 14 months to 18 years (catch-up programme) and of routine childhood immunisation at either ages 2 + 3 + 4 months, 5 + 6 months, or 14 months with a meningococcal C conjugate vaccine w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2d550e3a193e818a2651af4bf1eb408
https://doi.org/10.1016/j.vaccine.2004.06.019

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine

Autor: G van den Dobbelsteen, Clementien L. Vermont, Wendy Keijzers, H. H. van Dijken, L van Alphen, C. J. P. van Limpt, A. van der Ende, R. de Groot, A. J. Kuipers

Publikováno v: Infection and immunity, 71(4), 1650-1655. American Society for Microbiology
Infection & Immunity, 71(4), 1650-1655. American Society for Microbiology

The cross-reactivity of PorA-specific antibodies induced by a monovalent P1.7-2,4 (MonoMen) and/or a hexavalent (HexaMen) meningococcal B outer membrane vesicle vaccine (OMV) in toddlers and school children was studied by serum bactericidal assays (S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d87282c3a4cfb6e3678534dbae85932
https://doi.org/10.1128/iai.71.4.1650-1655.2003

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age

Autor: R. de Groot, G van den Dobbelsteen, H.C. Rumke, E. D. de Kleijn, G W van Omme, Lafeber Ab, Betsy Kuipers, L van Alphen, Rikard E Juttmann, H van Dijken, Jerry Labadie, M Wala

Publikováno v: Vaccine, 18, 1456-1466. Elsevier

To study the reactogenicity and immunogenicity of a hexavalent meningococcal outer-membrane-vesicle vaccine (OMV), two different dosages of this vaccine (7.5 and 15 microg of individual PorA proteins) consisting of vesicles expressing class 1 outer-m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aac0d530afdc06ef05f15a1c570e475
https://doi.org/10.1016/s0264-410x(99)00423-5